2022
An Evidence-based Physical Therapy Prescription for Adults With X-linked Hypophosphatemia
Kanamalla K, Fuchs R, Herzog C, Steigbigel K, Macica C. An Evidence-based Physical Therapy Prescription for Adults With X-linked Hypophosphatemia. Journal Of The Endocrine Society 2022, 6: bvac094. PMID: 35795809, PMCID: PMC9249973, DOI: 10.1210/jendso/bvac094.Peer-Reviewed Original ResearchAdult disordersConsiderable physical disabilityLower extremity ROMPhosphate-wasting disordersPhysical therapy prescriptionPhysical therapy recommendationsPT programKinetic chain exercisesPatient-centered studiesMusculoskeletal comorbiditiesExercise modificationsPatient goalsTherapy prescriptionFunctional improvementTherapy recommendationsClinical studiesActive rangeDaily livingProgression statusFunctional abilityXLHPhysical disabilityMinimal improvementFunctional effectsHypophosphatemia
2018
Vibrational spectroscopic analysis of hydroxyapatite in HYP mice and individuals with X-linked hypophosphatemia
Amenta E, King HE, Petermann H, Uskoković V, Tommasini SM, Macica CM. Vibrational spectroscopic analysis of hydroxyapatite in HYP mice and individuals with X-linked hypophosphatemia. Therapeutic Advances In Chronic Disease 2018, 9: 268-281. PMID: 30719271, PMCID: PMC6348532, DOI: 10.1177/2040622318804753.Peer-Reviewed Original ResearchUnaffected controlsPhosphate-wasting disordersWild-type micePersistent osteomalaciaDegenerative arthritisPeriodontal diseasePrimary teethPermanent teethFemoral cortical boneAdult disordersNeutral endopeptidaseHyp miceBone remodelingBiochemical milieuXLHCommon formCortical boneUse of dentinHypophosphatemiaSignificant differencesTeethInactivating mutationBoneUnaffected individualsMice
2017
Overview of Phosphorus-Wasting Diseases and Need for Phosphorus Supplements
Macica C. Overview of Phosphorus-Wasting Diseases and Need for Phosphorus Supplements. 2017, 185-200. DOI: 10.1201/9781315119533-14.Peer-Reviewed Original ResearchPhosphate-wasting disordersTumor-induced osteomalaciaTypical Western dietTotal body phosphorusNet intestinal absorptionIntestinal absorptionModerate hypophosphatemiaChronic casesWestern dietRenal phosphate-wasting disordersOral phosphate saltsRenal phosphate wastingSevere hypophosphatemiaChronic hypophosphatemiaMuscle painRenal functionBody phosphorusClinical presentationMetabolic disturbancesSuch therapyPhosphate wastingBone diseaseHigh-protein foodsPediatric disordersDietary load
2012
Mineralizing Enthesopathy Is a Common Feature of Renal Phosphate-Wasting Disorders Attributed to FGF23 and Is Exacerbated by Standard Therapy in Hyp Mice
Karaplis A, Bai X, Falet J, Macica C. Mineralizing Enthesopathy Is a Common Feature of Renal Phosphate-Wasting Disorders Attributed to FGF23 and Is Exacerbated by Standard Therapy in Hyp Mice. Endocrinology 2012, 153: 5906-5917. PMID: 23038738, PMCID: PMC3512070, DOI: 10.1210/en.2012-1551.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsExtracellular Matrix ProteinsFamilial Hypophosphatemic RicketsFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsGenetic Diseases, X-LinkedImmunohistochemistryKidneyMaleMiceMice, Inbred C57BLMice, TransgenicModels, GeneticMutationPedigreePhosphatesPhosphoproteinsRheumatic DiseasesTransgenesUp-RegulationConceptsPhosphate-wasting disordersStandard therapyFGF23 levelsElevated fibroblast growth factor 23Hyp miceRenal phosphate-wasting disordersFibroblast growth factor 23High FGF23 levelsGrowth factor 23Elevated FGF23 levelsAction of FGF23Dentin matrix acidic phosphoprotein 1Phosphate wasting disorderAutosomal recessive hypophosphatemic ricketsRecessive hypophosphatemic ricketsLigament insertion sitesChildhood managementOral phosphateFactor 23Achilles insertionDisease morbidityPotential morbidityBone spursUntoward effectsMurine model